The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder

@article{Kingsberg2015TheFS,
  title={The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder},
  author={Sheryl A Kingsberg and Anita H. Clayton and James G. Pfaus},
  journal={CNS Drugs},
  year={2015},
  volume={29},
  pages={915-933}
}
How a woman responds to sexual cues is highly dependent on a number of distinct, yet related, factors. Researchers have attempted to explain the female sexual response for decades, but no single model reigns supreme. Proper female sexual function relies on the interplay of somatic, psychosocial and neurobiological factors; misregulation of any of these components could result in sexual dysfunction. The most common sexual dysfunction disorder is hypoactive sexual desire disorder (HSDD). HSDD is… 

Figures and Tables from this paper

Hypoactive Sexual Desire Disorder International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review
TLDR
It is hypothesize that all these therapies alter central inhibitory and excitatory levels in hypoactive sexual desire disorder, and that ibanserin is the only Food and Drug Administration approved medication to treat premenopausal women with generalized acquired HSDD.
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.
TLDR
Overall, HSDD represents a common yet likely underrecognized disorder that midwives and other health care providers who care for women across the life span are in a unique position to address.
Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment.
TLDR
High prevalence and negative impact on the overall health and well-being of women, primary care health professionals and women's health practitioners need to be actively aware of HSDD, particularly because patients may be reluctant or unwilling to initiate a discussion about their sexual concerns during routine visits.
Hypoactive sexual desire disorder (HSDD) is not “female erectile dysfunction (ED)”: challenges with the characterization of HSDD in women based on a systematic literature review
TLDR
HSDD and ED are distinct conditions affecting different phases of the sexual response model, and thus require clear and unique clinical characterization and adequate communication between the health care professional and patient for appropriate diagnosis, management and treatment.
Evaluation and Management of Hypoactive Sexual Desire Disorder
Distressing Sexual Function at Midlife: Unmet Needs, Practical Diagnoses, and Available Treatments.
TLDR
Clinicians are provided with a framework to approach the discussion of FSD, to clinically identify FSD through patient symptoms and physical signs, and to manage FSD in perimenopausal and postmenopausal patients with the available U.S. Food and Drug Administration-approved and off-label treatments.
The Usage of Flibanserin to Treat Women ’ s Hypoactive Sexual Desire Disorder in the U . S .
TLDR
In 2015, the U. S. Food and Drug Administration approved the first prescription drug on the market designed specifically to treat HSDD in premenopausal women, called Addyi, and the drug’s efficacy, health risks, and potential implications on the pathologization of women's sexuality need to be critically assessed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 181 REFERENCES
Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM-V revisions: 2. For women with loss of subjective sexual arousal.
TLDR
Evidence presented that women with FSAD have clinically disordered sexual function is presented, but data suggest that the majority of these women withFSAD would meet none of the six proposed "A" criteria for Sexual Interest/Arousal Disorder, raising new validity and utility concerns for the proposed diagnostic classification.
Drugs in early clinical development for the treatment of female sexual dysfunction
TLDR
The aim of this paper is to provide the latest data on pharmacological treatments for FSD currently in Phase I and II clinical trials, withications in early phase trials show promise for the treatment of FSD.
Toward personalized sexual medicine (part 1): integrating the "dual control model" into differential drug treatments for hypoactive sexual desire disorder and female sexual arousal disorder.
TLDR
It is hypothesized that a single dose of 5-hydroxytryptamine receptor agonist (5-HT(1A)ra) will reduce the sexual-stimulation-induced PFC-mediated sexual inhibition during a short period after administration, and treatment with T+5- HT(1 a)ra will be more effective, in particular in women exhibiting sexual inhibition.
Sexual desire problems in women seeking healthcare: a novel study design for ascertaining prevalence of hypoactive sexual desire disorder in clinic-based samples of U.S. women.
TLDR
The prevalence of generalized acquired HSDD in women aged ≥18 who attended primary care or obstetrics and gynecology clinics for nonurgent clinic visits in the United States was observed, with markedly increased prevalence in midlife women.
Women's endorsement of models of female sexual response: the nurses' sexuality study.
TLDR
Findings suggest that the Basson model, currently advanced by the Second International Consultation on Sexual Medicine, may best reflect women with sexual concerns, rather than a single normative sexual response pattern.
Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM-V revisions: 1. For women with incomplete loss of desire or sexual receptivity.
TLDR
Additional data is provided to support the view suggesting that the proposed criteria would potentially exclude large numbers of women from diagnosis or treatment if they have moderate-to-marked (rather than severe) hypoactive sexual desire disorder (HSDD), or HSDD with incomplete loss of receptivity.
Hypoactive sexual desire disorder in menopausal women: a survey of Western European women.
TLDR
Sexual desire scores and sexual arousal, orgasm, and sexual pleasure were highly correlated, demonstrating that low sexual desire is frequently associated with decreased functioning in other aspects of sexual response.
Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study.
TLDR
In premenopausal women with HSDD, flibanserin 50 mg and 100’mg once daily at bedtime were well tolerated and associated with statistically significant improvements in SSE, sexual desire, and overall sexual function, and reduction of sexual distress, vs. placebo.
Prevalence and evaluation of sexual health problems--HSDD in Europe.
TLDR
The findings of this survey have implications for the understanding of hypoactive sexual desire disorder (HSDD), not only the way it should be assessed in clinical practice, but also the most appropriate means for its treatment.
...
1
2
3
4
5
...